New Drug Evaluation - Naldemedine for the treatment of opioid induced constipation

16th Dec 2019

The New Drug Evaluation for naldemedine for the treatment of opioid induced constipation is now available to stakeholders. This publication provides a concise, structured evaluation of the efficacy, safety, cost and potential place in therapy for this newly licensed product.

Visit our New Drug Evaluation page